Research Scientist - Translational Research
At Agensys, we're changing tomorrow by moving oncology forward. We've developed a pipeline of novel therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumors based on our own proprietary targets. We have discovered and validated a portfolio of clinically relevant targets in 14 different cancer types. Our pipeline includes therapeutic MAbs to multiple cancer indications that are at different stages of clinical and pre-clinical development.
Our parent company, Astellas Pharma US helps us shine. Together we are the bright spot in the pharmaceutical industry -- not just because of what we do, but in the way we do it. If you are looking for a company where you can change a life, make a dream come true, and light the way for a better tomorrow, this is the place for you.
Astellas, and our Agensys subsidiary, offer a different kind of work culture. A high standard of ethics is mandatory. Quality is our pledge. Diversity is valued. Individual initiative is rewarded. Astellas offers an environment where our employees can make a real difference. To continue to change tomorrow, Astellas/Agensys must recruit the best and brightest in the industry.
Come, shine with us!
Characterize Agensys' oncology targets and antibody therapeutics, including antibody-drug conjugates, with the purpose of guiding clinical studies by providing appropriate predictive, pharmacodynamic, efficacy and safety biomarker strategies.
Use of in vitro cell-based platforms to explore the biology of cancer targets, including their signal transduction pathways, mechanisms of action, and drug sensitivity/resistance.
In collaboration with the pharmacology group, investigate the efficacy and PK/PD relationships of Agensys' therapeutic antibodies, as monotherapy and in combinations, by designing in vivo experiments and also appropriate in vitro follow up studies.
Apply concepts developed from ongoing clinical studies results to the design, planning and execution of preclinical studies with the objective of enhancing current therapeutic modalities.
The incumbent will join an interdisciplinary team of scientists and research staff, developing novel anti-tumor antibody therapeutics. The position will involve both management and bench-level activities, and will require collaboration with other preclinical scientists in diverse fields of drug discovery as well as the with clinical group directing clinical studies.